The Rat Vascular Endothelial cell Growth Factor A-Cell Lysates (Rt VEGF-A) ELISA quantitates Rt VEGF-A in rat cell or tissue lysates. The assay will exclusively recognize both natural and recombinant Rt VEGF-A. Principle of the method The Rat VEGF-A…
Accession number
P16612
Dose range
0.82-200 pg/ml
Sensitivity of the dosage
2 pg/ml
Calibration range
2 pg/ml to 200 pg/ml
Dose
ELISA solid-phase sandwich
Brand
Invitrogen
The Rat Vascular Endothelial cell Growth Factor A-Cell Lysates (Rt VEGF-A) ELISA quantitates Rt VEGF-A in rat cell or tissue lysates. The assay will exclusively recognize both natural and recombinant Rt VEGF-A. Principle of the method The Rat VEGF-A…
The Rat Vascular Endothelial cell Growth Factor A-Cell Lysates (Rt VEGF-A) ELISA quantitates Rt VEGF-A in rat cell or tissue lysates. The assay will exclusively recognize both natural and recombinant Rt VEGF-A. Principle of the method The Rat VEGF-A solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples, standards, or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the addition of the second (detector) antibody, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of target present in the original specimen. Rigorous validation Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.
VEGF (vascular endothelial growth factor), which is a homodimer glycoprotein with disulfide bridges involved in 45 kDa angiogenesis, promotes tumour progression and metastases. VEGF has various effects on vascular endothelium, including the ability to promote endothelial cell viability, mitogenesis, chemotaxia and vascular permeability. VEGF's family currently includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and PIGF. The VEGF and its receptor system have proven to be the fundamental regulators of cell signaling of langenogenicity. Most tumours have the absolute requirement of angiogenesis and VEGF has been described as the most potent angiogenic cytokine associated with this process. To date, 5 different VEGF isoforms have been described. These isoforms are generated following an alternative splicing from a single VEGF gene. These isoforms bind to two tyrosine-kinase flt-1 (VEGFR-1) and flk-1/KDR (VEGFR-2) receptors, which express almost exclusively on endothelial cells. VEGF and its high affinity binding receptors, tyrosine kinases FLK1 and FLT1, would be important for the development of the embryonic vascular system. Studies have shown that an alternately spliced form of FLT1 produces a soluble protein, called sFLT1, which binds vascular endothelial growth factor with high affinity, acting as an inhibitor in angiogenesis. High levels of VEGF are associated with POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammapathy, skin changes), also known as Crow-Fukase syndrome, which affects several organs of the body.